Effects of a novel hepatitis B anti-viral drug E-CFCP in renal organic acid transporters

• Main Authors: Misaki Ishibane (Author), Hirofumi Hashimoto (Author), Meika Kaneko (Author), Shota Saito (Author), Sangjon Pae (Author), Shinpei Saito (Author), Yoshie Reien (Author), Yuri Hirayama (Author), Nobuyo Higashi-Kuwata (Author), Hiroaki Mitsuya (Author), Naohiko Anzai (Author)
• Format: Book
• Published: Elsevier, 2022-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Currently, the emergence of drug resistance is an important issue in the treatment of hepatitis B virus (HBV). Recently, our collaborating group developed a novel long-acting anti-HBV drug, E-CFCP. However, until this study, the effects of E-CFCP in the kidney have remained unclarified. Using cell v...